Comparison Chart Frazier Lifesciences Acquisition Corporation
Stocks
NAMS
NL00150012L7
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
2026-11-18
|
5-day change | 1st Jan Change | ||
| 19.74 EUR | +1.81% |
|
-1.99% | -43.73% |
| 11-04 | NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
| 11-04 | NewAmsterdam Pharma's Q3 Net Loss Narrows, Revenue Grows | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Bio Therapeutic Drugs | +1.81% | -1.99% | -43.73% | -47.65% | +101.02% | 2.21B |
-
|
-
|
-
|
Select your edition
All financial news and data tailored to specific country editions
















